Plug-shaped implant for the replacement and regeneration of biological tissue and method for preparing the implant - Patents.com

The plug-shaped implant with a bone anchor and cartilage-regenerating sections addresses the inadequacies of current osteochondral defect treatments by offering durable cartilage repair and regeneration, reducing the need for invasive joint replacement.

JP7584152B2Active Publication Date: 2024-11-15JOINTSPHERE BV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2021575059
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-06-27
Filing Date
2020-06-23
Publication Date
2024-11-15
Estimated Expiration
2040-06-23

Smart Images

  • Figure 0007584152000001
    Figure 0007584152000001
  • Figure 0007584152000002
    Figure 0007584152000002
  • Figure 0007584152000003
    Figure 0007584152000003
Patent Text Reader

Abstract

1. An implant for the replacement and regeneration of biological tissue in the form of a plug, comprising: a base section (2) configured to be fixed to bone tissue; a middle section (3) configured to replace cartilage tissue; and an upper section (4) configured to have cartilage tissue grown on and into it, wherein the middle and upper sections comprise the same thermoplastic elastomer material, which is porous in the upper section and non-porous in the middle section, and wherein the base section comprises a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% relative to the total volume of the polyaryletherketone polymer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an implant for the replacement and regeneration of living tissue in the form of a plug.The present invention particularly relates to an implant for the replacement and regeneration of osteochondral structures in the form of a plug.The present invention further relates to a method for the preparation of the implant and to an osteochondral structure comprising the implant. [Background technology]

[0002] Osteochondral structures refer to structures that include cartilage and bone. Typical osteochondral structures are found in the femur (thigh bone), tibia (shin bone), and kneecap (patella). Such structures fit together and move smoothly because the bone surfaces are covered with a relatively thick layer of articular (hyaline) cartilage. An (osteochondral) defect is any type of damage to the articular cartilage and optionally the underlying (subchondral) bone. Usually, (osteochondral) defects appear in certain weight-bearing spots, for example, at the ends of the femur and tibia, and behind the kneecap. They can range from rough cartilage, small bone and cartilage fragments that impede movement, to complete cartilage loss.

[0003] Trauma to the articular surface is common in young active people playing sports or as a sequela of accidents. The damage may involve only the cartilage layer, but often also the underlying subchondral bone. Articular cartilage has a very low tendency to heal, and the repair tissue is qualitatively inferior to the original tissue. This invariably leads over the years to the formation of osteoarthritis (OA), which is the main cause of disability and reduced quality of life in the elderly. The standard treatment for this condition is eventually joint replacement with an artificial joint. Although clinically effective, non-biological implants do not last longer than 10-20 years, and revision surgery is much less effective and very costly. For this reason, much research is devoted to the development of biological regenerative therapies that last a lifetime. However, despite promising in vitro results, so far no single solution has proven to be more effective than the current standard of care over the long term in real life conditions.

[0004] Because the cartilage layer lacks nerve fibers, patients are often unaware of the severity of the damage. In the final stages, the affected joint is composed of bone rubbing against bone, leading to severe pain and limited mobility. By the time the patient seeks medical treatment, surgical procedures may be required to relieve pain and repair the cartilage damage. To avoid or postpone such surgical procedures, implants for joints have been developed. These may be implanted into the bone structure at an early stage of cartilage damage and thus may be offered for preventative treatment to avoid unnoticed degeneration of the joint.

[0005] Many treatments are available to treat articular cartilage damage in joints such as the knee, starting from the most conservative and non-invasive options, to total joint replacement if the damage has spread throughout the joint. Currently available treatments include anti-inflammatory drugs in the early stages. These can reduce pain, but have limited effect on arthritic symptoms and do not further repair the joint tissue. Cartilage repair methods such as arthroscopic debridement attempt to at least slow the degeneration of the tissue. However, these methods are only partially effective in repairing the soft tissue and do not restore joint spacing or improve joint stability. Joint replacement (arthroplasty) is considered the final solution when all other options to reduce pain and restore mobility have failed or are no longer effective. Although arthroplasty can be effective, the procedure is extremely invasive and technically challenging, which may impair future treatment options. Cartilage regeneration has also been attempted, especially by tissue engineering techniques. The use of cells, genes and growth factors in combination with scaffolds plays a fundamental role in the regeneration of functional and viable articular cartilage. All of these approaches are based on encouraging the body's normal healing or repair processes at the cellular level. Many of these compounds are delivered in a variety of carriers or matrices, including woven polylactic acid-based polymers or collagen fibers. Despite various attempts to regenerate cartilage, there is currently no reliable and proven treatment for repairing articular cartilage defects.

[0006] Another standard treatment is to treat smaller lesions (≤2cm 2 ) for microfractures (MFx), and for larger damage (>2cm 2 However, the cartilage tissue regenerated by these techniques cannot withstand the biomechanical challenges of the joint and begins to degenerate already within 18 months. It is therefore not possible to significantly delay, much less prevent, the replacement of the joint with an artificial joint. Summary of the Invention

[0007] The object of the present invention is to provide an implant for the replacement and regeneration of biological tissue in the form of a plug with improved load distribution and cartilage regeneration properties. Another object is to provide such an implant in the form of a plug for the replacement and regeneration of osteochondral structures. Yet another object is to provide a method for the preparation of the implant. The present invention further aims to provide an implant that can repair articular cartilage damage in a durable manner, at least postponing and preferably preventing joint replacement with an artificial joint.

[0008] These and other objects are provided by a plug-shaped implant according to claim 1. The implant according to the invention comprises an implant in the shape of a plug, comprising a base section configured for anchoring to bone tissue, a middle section configured for replacing cartilage tissue and a top section configured for growing cartilage tissue on and into it, the middle and top sections comprising the same thermoplastic elastomeric material, which is porous in the top section and substantially non-porous in the middle section, and the base section comprises a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% relative to the total volume of the polyaryletherketone polymer.

[0009] Substantially non-porous material in the context of the present invention means a material with a porosity of less than 20%, preferably at most 10%, more preferably at most 5%, even more preferably at most 1% of the total volume of the material. Porous materials contain pores, defined as fine openings. The pores may be micropores with a diameter of less than 1 mm, or macropores with a diameter of more than 1 mm. The pores may be interconnected, which is preferred, meaning that the pores are internally connected or there is continuity between parts or elements. Non-porous material in the context of the present invention does not mean a material that is impermeable to molecules of any size, although some small molecules may actually be able to pass through the non-porous material. Rather, non-porous material in the context of the present invention refers to a material that is impermeable to synovial fluid and / or blood.

[0010] The pore size of the porous portion of the implant can be selected from 100 to 1000 microns, more preferably from 100 to 500 microns, and most preferably from 300 to 500 microns.

[0011] The materials used in the implants of the present invention are preferably biocompatible, which means that they can coexist with living tissues or organisms without harming them. Furthermore, the implants according to the present invention are substantially non-biodegradable, combining cartilage replacement and cartilage regeneration. Non-biodegradable materials in the context of the present invention mean materials that are not decomposed into less complex compounds or compounds with fewer carbon atoms by the environment of the implanted implant. The weight average molecular weight of substantially non-biodegradable materials decreases by at most 20%, more preferably at most 10%, even more preferably at most 5%, even more preferably at most 1% with respect to the original weight average molecular weight after one year of implantation.

[0012] The base section of the plug-shaped implant functions as a bone anchor, while the combination of the middle and top sections functions as a partial replacement of damaged cartilage and as a scaffold for cartilage regeneration. In a plug-shaped implant, the top section refers to the section closest to the cartilage phase when implanted. The base section refers to the section furthest from the cartilage phase when implanted. The middle section is located between the top and base sections.

[0013] The cross section of the plug-shaped implant through a horizontal or vertical plane can have any suitable shape. The cross section can be circular, square, or polygonal, such as hexagonal, octagonal, or decagonal. In some embodiments, the plug-shaped implant can be tapered to be shaped as a truncated cone structure. Preferably, the implant has a smaller cross section at the base section than at the top section. The cross section (or diameter in the case of a cylindrical implant) can vary continuously between the base and top sections, or can show discontinuities, for example, at the interface between the sections.

[0014] If the implant has a tapered profile, the angle of the taper is preferably between 1° and 45°. In some embodiments, the taper is about 3° to 30°, more preferably between 5° to 30°, and even more preferably between 10° to 15°. The tapered profile may facilitate insertion of the implant into the osteochondral defect and further reduce the potential for damage to the host tissue.

[0015] Useful embodiments of the present invention provide implants in which the base section comprises a core of a non-porous polyaryletherketone polymer and a circumferential shell, preferably of a porous polyaryletherketone polymer, the shell having a thickness of less than 10% of the maximum diameter of the base section. Other useful embodiments provide implants in which the (circumferential) shell has a thickness of less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of the maximum diameter of the base section. Alternatively, the cross-sectional area of ​​the (circumferential) shell occupies up to 35% of the maximum cross-sectional area of ​​the base section. Other useful embodiments provide implants in which the cross-sectional area of ​​the circumferential shell is less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 3%, or less than 1% of the maximum cross-sectional area of ​​the base section.

[0016] Another embodiment of the present invention provides an implant in which the base section extends between the top and bottom surfaces and includes a layer of porous polyaryletherketone polymer, the layer adjacent the top surface having a thickness that is less than 10% of the maximum height of the base section, and the pores of the polyaryletherketone polymer in the layer, preferably all pores, include a biocompatible elastomeric material. In other embodiments, the layer adjacent the top surface has a thickness that is less than 10%, less than 8%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of the maximum height of the base section. All of the above embodiments can improve the adhesion of the middle section (and top section) to the base section to various degrees. At the same time, the mechanical properties of the base section and the support provided by the base section to the implant are maintained at an appropriate level.

[0017] In another embodiment of the invention, the top surface of the base section of the implant includes irregularities or undulations. The irregularities may include, for example, ridges having a sawtooth shape. The undulations may be irregular or regular, such as having a sinusoidal shape.

[0018] Another useful embodiment relates to an implant in which the base section includes a centrally located cavity containing a biocompatible elastomeric material. Such a cavity can further improve adhesion of the middle section (and the top section) to the base section. The cavity may be cylindrical and its cross section may be square or polygonal. The walls of the cavity may also be provided with irregularities or undulations, or may include sections of cross section larger than its average cross section. Several of such cavity sections may be provided at different heights of the base section to form a mechanical locking structure.

[0019] A preferred embodiment of the present invention provides an implant in which the base section comprises a non-porous polyaryletherketone polymer, and more preferably comprises a central cavity associated with the base section.

[0020] To further improve adhesion between the base section and the middle (and top) section, an embodiment of the present invention provides an implant in which the base section further comprises a phosphate mineral, including apatite, more preferably hydroxylapatite, fluoroapatite, and / or chloroapatite, most preferably hydroxylapatite. The phosphate mineral may be provided on the exterior surface of the base section or may be provided within the pores of the base section.

[0021] Yet another embodiment provides an implant in which the base section includes an external surface having irregularities or undulations. Such external surface irregularities may include, for example, ridges having a sawtooth shape, for example extending circumferentially on (a part of) the external surface of the base section. The undulations may be irregular or regular, such as having a sinusoidal shape. The undulations may also extend circumferentially on (a part of) the external surface of the base section. The irregularities and undulations may be provided by casting the material in a suitably profiled mold, or may be provided by machining, for example by rotary milling of a molded implant.

[0022] The polyaryletherketone (PAEK) polymer of the base section comprises a semi-crystalline thermoplastic polymer containing alternating ketone (R-CO-R) and ether groups (ROR). The linking group R between the functional groups comprises a 1,4-substituted aryl group. The PAEK polymers used in the base section may include, among others, PEK (polyetherketone), PEEK (polyetheretherketone), PEKK (polyetherketoneketone), PEEKK (polyetheretherketoneketone) and PEKEKK (polyetherketoneetherketoneketone). Due to its excellent resistance to hydrolysis, the polyaryletherketone polymer of the base section is advantageously used in the implants of the invention. It does not degrade when sterilized or when implanted in the body for an extended period of time. It is also found to bond particularly well to the elastomeric material of the middle and upper sections. The polyaryletherketone polymer of the base section may be used as is or, in one embodiment, may comprise a reinforcing material selected from the group consisting of fibrous or particulate polymers and / or metals.

[0023] According to the invention, the material of the middle and upper sections comprises the same thermoplastic elastomer material. This means that at least its components are chemically the same. As will be described herein below, some physical properties may differ, for example their weight average molecular weight. In a particularly preferred embodiment, the thermoplastic elastomer material comprises a linear block copolymer comprising urethane and urea groups and is substantially free of added peptide compounds having cartilage regeneration properties. Surprisingly, it has been found that the implant of the invention is capable of regenerating cartilage tissue and thus avoids the use of any functional compound exhibiting cartilage regeneration properties. In particular, it has been found that the implant according to this embodiment does not require the use of peptides, for example those comprising the RGD sequence. These compounds are said to allow the binding of integrins and thereby promote cell adhesion. Preferably, the thermoplastic elastomer material is substantially free of any added compounds having cartilage regeneration properties.

[0024] The thermoplastic elastomer material of the implant according to the embodiment of the invention comprises linear block (or segmented) copolymers. Such copolymers contain "hard" crystallized blocks of polyurethane and / or polyurea segments, and may also contain "hard" crystallized blocks of polyester and / or polyamide between the "soft" blocks. At room temperature, the low melting "soft" blocks may not be compatible with the high melting "hard" blocks, causing phase separation by crystallization or liquid-liquid separation. These copolymers show reversible physical crosslinks due to the crystallization of the "hard" blocks of the segmented copolymers. Thermoplastic elastomers can be molded into any shape at higher temperatures, more specifically above the melting point of the "hard" blocks. On the other hand, thermoplastic elastomers offer mechanical stability and elasticity at low temperatures, i.e. at typical body temperatures. This makes these materials particularly suitable as replacement materials for human or animal cartilage.

[0025] In another preferred embodiment of the implant of the invention, the thermoplastic elastomer material further comprises a carbonate group. This embodiment proves to be beneficial in that its mechanical properties are well matched to those of human or animal cartilage. Surprisingly, the use of this embodiment in implanted implants improves cartilage regeneration.

[0026] A particularly preferred embodiment of the present invention provides an implant wherein the thermoplastic elastomeric material comprises poly-urethane-bisurea-alkylene carbonate, more preferably poly-urethane-bisurea-hexylene carbonate.

[0027] The thermoplastic elastomer component may generally include three components: a long-chain diol, for example with a polyether, polyester or polycarbonate backbone, a difunctional di-isocyanate, and finally a chain extender, such as water, another (sometimes short-chain) diol, or a diamine. The latter chain extenders are preferred because they provide bis-urea units to the thermoplastic elastomer.

[0028] Preferred are embodiments of the implant in which the thermoplastic elastomer material is aliphatic. This means that all components of the thermoplastic elastomer are devoid of aromatic groups and contain only aliphatic groups. The thermoplastic elastomers of the present invention can be prepared in a one-pot process in which a long-chain diol is first reacted with an excess of a di-isocyanate to form an isocyanate-functionalized prepolymer. The latter is then reacted with a chain extender, such as a preferred diamine, resulting in the formation of a high molecular weight thermoplastic elastomer polymer containing urethane groups. When a diamine is used as a chain extender, the thermoplastic elastomer also contains bis-urea groups, which is preferred.

[0029] The synthetic procedures for preparing thermoplastic elastomers can lead to a distribution of "hard" block lengths. As a result, the phase separation of these block copolymers can be incomplete, with some of the "hard" blocks, especially the shorter blocks, dissolving in the soft phase, causing an increase in the glass transition temperature. This is less desirable for the low temperature flexibility and elasticity of the thermoplastic elastomer materials in the upper and middle sections. The polydispersity of the "hard" blocks is manifested as a wide melting range and a temperature-dependent rubbery plateau in dynamic mechanical thermal analysis (DMTA). Thus, preferred embodiments include elastomeric block copolymers containing "hard" blocks of substantially uniform length. These can be prepared by fractionation of a mixture of "hard" block oligomers and subsequent copolymerization of uniform "hard" block oligomers of a specific length (or change in length) with the prepolymers described above.

[0030] Thermoplastic elastomers can be prepared by chain extension reaction of isocyanate-functionalized prepolymers with diamines, but also amine-functionalized prepolymers with di-isocyanates. Examples of suitable commercially available diamines and di-isocyanates include alkylenediamines and / or di-isocyanates, arylenediamines and / or di-isocyanates. Amine-functionalized prepolymers are also commercially available or can be prepared from (readily available) hydroxy-functionalized prepolymers by cyanoethylation followed by reduction of the cyano group, by Gabriel synthesis (halogenation or tosylation followed by modification with phthalimide and finally deprotection of the phthalimide group to give a primary amine), or by other methods known in the art. Isocyanate-functionalized prepolymers can be prepared by reaction of hydroxy-functionalized prepolymers with di-isocyanates such as, for example, isophorone di-isocyanate (IPDI), 1,4-diisocyanatobutane, 1,6-diisocyanatohexane or 4,4'-methylenebis(phenylisocyanate). Alternatively, isocyanate-functionalized prepolymers can be prepared from amine-functionalized prepolymers, for example, by reaction with di-tert-butyl tricarbonate. Hydroxy-functionalized prepolymers of any kind of composition, typically with molecular weights ranging from about 500 g / mol to about 5000 g / mol, are also advantageously used. Examples include polyethers such as polyethylene glycol, polypropylene glycol, poly(ethylene-co-propylene) glycol and poly(tetrahydrofuran), polyesters such as poly(caprolactone) or polyadipate, prepolymers of polycarbonates, polyolefins, hydrogenated polyolefins such as poly(ethylene-butylene), etc. Polycarbonates are preferred.

[0031] The implant is preferably used without any attachment means and remains in the osteochondral structure due to its shape and the surrounding tissue structure. The implant can be used in the knee, but also in other joints such as the temporomandibular joint of the temporal bone, the ankle, the hip joint, the shoulder, etc.

[0032] The thermoplastic elastomers used in the upper and middle sections of the implant are particularly advantageous since they can adapt their mechanical properties to those of human and animal cartilage. In one embodiment of the present invention, the implant can be provided in which the elastomer material of the middle section has an elastic modulus at room temperature of less than 10 MPa, more preferably less than 8 MPa, less than 7 MPa, less than 6 MPa, less than 5 MPa, less than 4 MPa, less than 3 MPa or less than 2 MPa.

[0033] In the context of the present application, room temperature means a temperature in the range of 20-30°C, more preferably 25°C.

[0034] Similarly, preferred embodiments of the implant include a top section in which the porous elastomeric material of the top section has a modulus at room temperature that is less than 80%, more preferably less than 50%, even more preferably 10-50%, even more preferably 15-40%, and most preferably 20-30% of the modulus of the elastomeric material of the middle section. Such a reduction in modulus can be achieved by modifying the porosity of the material of the middle section or by modifying the physical properties of the material of the middle section, for example by modifying its weight average molecular weight.

[0035] The porosity of the elastomeric material of the upper section can be selected within wide limits: preferred porosities of the elastomeric material of the upper section are selected from 20 to 80% by volume, more preferably from 30 to 70% by volume, even more preferably from 40 to 60% by volume, most preferably from 45 to 55% by volume.

[0036] Useful embodiments of the present invention provide implants in which the midsection comprises a core of non-porous elastomeric material and a circumferential shell, preferably of porous elastomeric material, the shell having a thickness of less than 10% of the maximum diameter of the midsection. Other useful embodiments provide implants in which the (circumferential) shell has a thickness of less than 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the maximum diameter of the midsection. The maximum diameter is appropriate, for example, in embodiments in which the plug-shaped implant is tapered and has a circular cross-section. Alternatively, the cross-sectional area of ​​the (circumferential) shell occupies up to 35% of the maximum cross-sectional area of ​​the midsection. Other useful embodiments provide implants in which the cross-sectional area of ​​the (circumferential) shell is less than 30%, 25%, 20%, 15%, 10%, 5%, 3%, or 1% of the maximum cross-sectional area of ​​the midsection. The maximum cross-sectional area is appropriate, for example, in embodiments in which the plug-shaped implant is tapered.

[0037] Embodiments having the above disclosed preferred combination of mechanical properties of the upper and mid-sections tend to promote cartilage regeneration, which is believed to be due to favorable stress (re)distribution in the osteochondral structure containing the implant during (dynamic) loading.

[0038] The height of the plug-shaped implant can be selected depending on the specific application in the body. The height can vary, for example, in the range of 3-18 mm. According to a useful embodiment of the present invention, an implant is provided in which the height of the base section, the height of the non-porous middle section, and the height of the porous top section are selected such that the top surface of the implant is below the top surface of the cartilage present on the osteochondral structure when implanted, preferably over a distance of 0.1-1 mm. This embodiment encourages the growth of cartilage tissue not only in but also on the top section, thereby building a strong anchorage between the top section and the newly formed cartilage. It has been found that chondrocytes from the host cartilage have a strong affinity for the segmented elastomer of the top section and therefore tend to colonize its surface to generate new hyaline cartilage tissue on the top of the implant.

[0039] Another embodiment provides an implant in which the height of the base section, the height of the non-porous middle section, and the height of the porous top section are selected such that the bottom surface of the middle section, when implanted, is approximately the same height as the bottom surface of the cartilage present on the osteochondral structure.

[0040] Yet another embodiment of the present invention provides an upper section whose upper surface is slightly curved. The preferred radius of curvature of the upper surface of the upper section in the sagittal plane is selected in the range of 15-150 mm, more preferably 17-125 mm, even more preferably 19-100 mm, even more preferably 21-75 mm, even more preferably 23-50 mm, and most preferably 25-30 mm. This embodiment allows for regenerating a new cartilage layer on the upper surface of the upper section of the implant, with a thickness that is approximately equal across the upper surface. The result is that the radius of the upper surface of the regenerated cartilage can be, i.e., approximately the same as the radius of the surrounding native cartilage layer adjacent to the implant, thereby showing a continuity of radii. The upper surface of the upper section of the implant can also be curved in the medial-lateral plane, preferably with a radius of curvature having the range disclosed above for the sagittal plane. In a practical embodiment, the upper surface of the upper section of the implant has equal radii of curvature in the sagittal and medial-lateral planes. This embodiment therefore comprises a spherical upper surface.

[0041] Another aspect of the present invention provides a method for preparing an implant, comprising the steps of: a) providing in a mold at room temperature a base section comprising a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% relative to the total volume of the polyaryletherketone polymer, and granules of a thermoplastic elastomer material on top of the base section; b) closing the mold and heating the assembly to a temperature of 100° C.-250° C. under a pressure of 1-2 GPa such that the thermoplastic elastomer material melts and fuses with the base section; c) cooling the assembly to room temperature to solidify the thermoplastic elastomer material and opening the mold; and d) providing pores in the top section of the thermoplastic elastomeric material either before or after the mold is opened.

[0042] Another embodiment of the invention provides a method in which, after step b), the mould is opened, additional granules of thermoplastic elastomer material are added to the mould and step b) is repeated. The amount of material added in the two-step embodiment of this method can be selected within wide limits. Increasingly better results are obtained if the ratio between the first and second addition of granules of thermoplastic elastomer material is selected from 01:99 to 99:01, more preferably from 30:70 to 97:03, most preferably from 70:30 to 95:05.

[0043] Another embodiment of the present invention provides a process, wherein the heating temperature in step b) is between 110° C. and 225° C., more preferably between 120° C. and 200° C., most preferably between 130° C. and 175° C. The preferred pressure in all the cited temperature ranges is between 1.1 and 1.8 GPa, more preferably between 1.2 and 1.6 GPa. [Brief description of the drawings]

[0044] The invention will now be further illustrated by the following figures and examples, without however being limited thereto. [Figure 1A-1D] 1A-1D show schematic side views of four embodiments of exemplary implants according to the present invention. [Figure 2A] FIG. 2 shows a schematic perspective view of a base section according to an embodiment of the present invention. [Figure 2B] FIG. 2B shows a schematic cross-sectional view of the embodiment of FIG. 2A. [Figure 2C-D] 2C shows a schematic detail view of parts B and C of the embodiment of FIG. 2B. [Diagram 3] FIG. 1 shows a schematic diagram of a possible synthetic route to a thermoplastic polycarbonate material according to an embodiment of the present invention. [Figure 4] 1 shows a 1H-NMR spectrum of a thermoplastic polycarbonate material according to an embodiment of the present invention. [Figure 5A-5C] 1 shows DSC thermograms of a thermoplastic polycarbonate material according to an embodiment of the present invention at different heating rates. [Figures 6A-6C]6A-6C show schematic diagrams of an osteochondral defect (6A), an osteochondral structure including an implant according to an embodiment of the invention (6B), and the same osteochondral structure after cartilage overgrowth (6C). [Figure 7A-7D] 1 shows schematic side views of four embodiments of an implant according to yet another embodiment of the present invention; [Figure 8A-8C] 8A-8C show schematic diagrams of an osteochondral defect, an osteochondral structure including an implant according to another embodiment of the invention (8B), and the same osteochondral structure after cartilage overgrowth (8C).

[0045] Referring to FIG. 1A, a side view of an exemplary embodiment of an implant according to the present invention is shown. The implant 1, in the shape of a plug, comprises a base section 2 configured to be fixed to bone tissue, a middle section 3 configured to replace cartilage tissue, and a top section 4 configured to allow cartilage tissue to grow on and into it. The middle section 3 and the top section 4 comprise the same thermoplastic elastomer material. The thermoplastic elastomer material in this embodiment comprises poly-urethane-bisurea-hexylene carbonate, the preparation and properties of which are further described below. However, the top section 4 comprises a porous poly-urethane-bisurea-hexylene carbonate, while the middle section 3 comprises the same poly-urethane-bisurea-hexylene carbonate without any pores. The base section 2 comprises a non-porous polyaryletherketone polymer, which in the embodiment shown is a non-porous PEKK polymer. The implant 1 is cylindrical and has a diameter 10 of 6 mm. The height 20 of the base section 2, the height 30 of the mid section 3 and the height 40 of the top section 4 add up to a total height of 6mm.

[0046] FIG. 1B represents a schematic side view of another embodiment of an implant according to the invention. The embodied implant 1 in the form of a plug again comprises a base section 2 configured for anchoring to bone tissue, a middle section 3 configured for replacing cartilage tissue, and a top section 4 configured for growing cartilage tissue on and into it. The middle section 3 and the top section 4 comprise the same poly-urethane-bisurea-hexylene carbonate material, which is porous in the top section 4 and non-porous in the middle section 3. The base section 2 comprises a substantially non-porous PEKK polymer having a porosity of less than 20% relative to the total volume of the PEKK polymer. The base section 2 of this embodiment comprises in particular a core 21 of non-porous PEKK polymer and a circumferential shell 22 of porous PEKK polymer. The shell 22 has a thickness 23 of about 8% of the diameter 10 of the base section 2 (and of the implant 1). The base section 2 further extends between the top surface 24 and the bottom surface 25 and includes a layer 26 of porous PEKK polymer adjacent the top surface 24 and having a thickness 27 of about 8% of the height 20 of the base section 2. The pores of the PEKK polymer of layer 26 originate from the middle section 3 and include a biocompatible poly-urethane-bisurea-hexylene carbonate that has infiltrated the pores of the PEKK polymer of layer 26 during manufacture. The method of manufacture of the implant is further described below. As with the embodiment of FIG. 1A, the implant 1 is cylindrical and has a diameter 10 of 6 mm. The height 20 of the base section 2, the height 30 of the middle section 3, and the height 40 of the top section 4 add up to a total height of 6 mm.

[0047] 1C represents a schematic side view of yet another embodiment of an implant according to the invention. The embodied implant 1 in the form of a plug again comprises a base section 2 configured to be fixed to bone tissue, a middle section 3 configured to replace cartilage tissue, and a top section 4 configured to grow cartilage tissue on and into it. The middle section 3 and the top section 4 comprise the same poly-urethane-bisurea-hexylene carbonate material, which is porous in the top section 4 and substantially non-porous in the middle section 3. The base section 2 comprises a substantially non-porous PEKK polymer having a porosity of less than 20% relative to the total volume of the PEKK polymer. The base section 2 of this embodiment in particular extends between a top surface 24 and a bottom surface 25 and comprises a layer 26 of porous PEKK polymer, which layer 26 is adjacent to the top surface 24 and has a thickness 27 of about 8% of the height 20 of the base section 2. The pores of the PEKK polymer of layer 26 originate from mid-section 3 and include biocompatible poly-urethane-bisurea-hexylene carbonate that has infiltrated the pores of the PEKK polymer of layer 26 during manufacture. Mid-section 3 of this embodiment specifically includes a core 31 of non-porous poly-urethane-bisurea-hexylene carbonate polymer and a circumferential shell 32 of porous poly-urethane-bisurea-hexylene carbonate polymer. Shell 32 has a thickness 33 of about 8% of the diameter 10 of mid-section 3 (and implant 1). Base section 2 further extends between top surface 24 and bottom surface 25 and includes a layer 26 of porous PEKK polymer adjacent top surface 24 and having a thickness 27 of about 8% of the height 20 of base section 2. The dimensions and shape are the same as the embodiment of Figures 1A and 1B.

[0048] FIG. 1D shows a schematic side view of yet another embodiment of an implant according to the invention. The embodied implant 1 in the form of a plug corresponds to that shown in FIG. 1C. In addition, the intermediate section 3 of this embodiment has a circumferential shell 32 of porous poly-urethane-bisurea-hexylene carbonate polymer, which here has a thickness 33 of about 10% of the diameter 10 of the intermediate section 3 (and of the implant 1). Furthermore, the base section 2 comprises a layer 26 of porous PEKK polymer, which is adjacent to the upper surface 24 and has a thickness 27 of about 5% of the height 20 of the base section 2. The pores of the PEKK polymer of the layer 26 originate from the intermediate section 3 and comprise biocompatible poly-urethane-bisurea-hexylene carbonate, which has infiltrated the pores of the PEKK polymer of the layer 26 during manufacture. The base section 2 further comprises a core 21 of non-porous PEKK polymer and a circumferential shell 22 of porous PEKK polymer. The shell 22 has a thickness 23 that is about 5% of the diameter 10 of the base section 2 (and implant 1). Finally, the base section 2 also includes a layer 28 of porous PEKK polymer adjacent the bottom surface 25 and having a thickness 29 that is about 5% of the height 20 of the base section 2. The dimensions and shape are the same as the embodiment of Figures 1A-1C.

[0049] 1B, 1C, and 1D, the circumferential shells (22, 32) are shown in cross section to show their respective thicknesses (23, 33). In side view, they extend across the entire diameter 10 of the implant 1.

[0050] Referring to Figure 7A, a side view of another embodiment of an implant according to the invention is shown. The implant 1 in the form of a plug comprises the same materials and sections as shown in Figure 1A. The dimensions of the implant in Figure 7A are the same as those of the implant in Figure 1A, with one exception. Instead of having a flat upper surface 41 of the upper section 4 (and thus the implant 1) as in Figure 1A, the upper surface 41a of the upper section 4 is spherical with a radius of curvature R of about 28 mm (not drawn to scale).

[0051] Referring to Figure 7B, a side view of another embodiment of an implant according to the invention is shown. The implant 1 in the form of a plug comprises the same materials and sections as shown in Figure 1B. The dimensions of the implant in Figure 7B are the same as those of the implant in Figure 1B, with one exception. Instead of having a flat upper surface 41 of the upper section 4, as in Figure 1B, the upper surface 41a of the upper section 4 is spherical with a radius of curvature R of about 28 mm (not drawn to scale).

[0052] Referring to Figure 7C, a side view of another embodiment of an implant according to the invention is shown. The implant 1 in the form of a plug comprises the same materials and sections as shown in Figure 1C. The dimensions of the implant in Figure 7C are the same as those of the implant in Figure 1C, with one exception. Instead of having a flat upper surface 41 of the upper section 4, as in Figure 1C, the upper surface 41a of the upper section 4 is spherical with a radius of curvature R of about 28 mm (not drawn to scale).

[0053] Referring to Fig. 7D, a side view of another embodiment of an implant according to the invention is shown. The implant 1 in the form of a plug comprises the same materials and sections as shown in Fig. 1D. The dimensions of the implant in Fig. 7D are the same as those of the implant in Fig. 1D, with one exception. Instead of having a flat upper surface 41 of the upper section 4, as in Fig. 1D, the upper surface 41a of the upper section 4 is spherical with a radius of curvature R of about 28 mm (not drawn to scale).

[0054] Again, note that in Figures 7B, 7C, and 7D, the circumferential shells (22, 32) are shown in cross section to show their respective thicknesses (23, 33). In side view, they extend across the entire diameter 10 of the implant 1 (not drawn to scale).

[0055] 2A-2D, an embodiment of the base section 2 of the implant 1 of the present invention is shown in a schematic manner. The base section 2 shown is essentially cylindrical in shape with a diameter 10 and a height 20. The upper surface 24 of the base section has a circumferentially flat rim portion 240 that gradually extends into a centrally located cavity 241. The cavity 241 is provided with a locking portion 242 having a diameter larger than the diameter of the cavity 241. As shown in detail in FIG. 2C, the locking portion 242 of the cavity 241 is disc-shaped, whereby the outer rim of the disc forms an angle 246 of 1°-20°, more preferably 5°-15°, with the longitudinal direction 247 of the base section 2. During the manufacture of the implant, the cavity 241 (and portion 242) is filled with a portion of a biocompatible elastomeric material to properly fix the intermediate section 3 to the base section 2. As mentioned above, the base section 2 comprises a PEKK polymer which may be non-porous or substantially non-porous, the latter embodiment including the examples disclosed above. The base section 2 is further seen to include an exterior surface having irregularities or undulations. In this embodiment, these include circumferential ridges 243 which are sawtooth shaped in cross section, as shown in detail in Figure 2D. The angle 244 at which the sawtooth sides extend relative to the lateral direction 245 of the base section 2 is preferably between 70° and 85°, more preferably between 75° and 80°.

[0056] Preparation of elastomeric materials for the upper and middle sections The aliphatic poly-urethane-urea-hexylene carbonate biomaterials of the middle section 3 and top section 4 were prepared as follows (see FIG. 3). Poly(hexylene carbonate) diol (23.9 g, 11.9 mmol) was weighed into a 500 mL three-neck flask and dried by heating to 75° C. overnight under reduced pressure, after which it was cooled to room temperature. Under an argon atmosphere, 1,6-diisocyanatohexane (4.1 g, 23.9 mmol), DMAc (20 mL) and one drop of Sn(II) bis(2-ethylhexanoate) were added, and the mixture was then heated and stirred for 3 hours, resulting in an increase in viscosity. The mixture was cooled to room temperature, diluted with DMAc (100 mL) and a solution of 1,6-diaminohexane (1.4 g, 11.9 mmol) in DMAc (50 mL) was added in one portion with thorough mixing. Upon addition and mixing, a gel formed immediately. The mixture was further diluted with DMAc (150 mL) and heated in an oil bath at 130 °C to give a homogeneous viscous slurry. After cooling to room temperature, the mixture was precipitated in a water / brine mixture (2.75 L water + 0.25 L saturated brine) to give a soft white material. This material was cut into smaller pieces and stirred in a 1:5 mixture of methanol and water (3 L) for 64 h. After decanting the supernatant, the resulting solid was stirred in a 2:1 mixture of methanol and water (0.75 L) for 6 h. The supernatant was decanted and stirred in a 2:1 mixture of methanol and water (0.75 L) for 16 h, the supernatant was decanted, and the solid was dried under reduced pressure at 70 °C to give a flexible, tough, elastomeric polymer.

[0057] The resulting polymers were analyzed using a Varian 200, Varian 400MHz, or 400MHz Bruker spectrometer at 298K. 1 H NMR spectroscopy was performed. DSC was performed using a Q2000 machine (TA Instruments). Heating scan rates of 10° C. / min and 40° C. / min were used to evaluate the melting temperature (Tm) and glass transition temperature (Tg), respectively. Tm was determined by the peak melting temperature and Tg was determined from the inflection point.

[0058] All reagents, chemicals, materials, and solvents were obtained from commercial sources and used without further purification. The poly(hexylene carbonate) diol used had an average molecular weight of about 2 kg / mol. Figures 4 and 5 show the solubility of the resulting polymer, respectively. 1 The H NMR spectrum and DSC thermogram are shown. 1 The results of the H NMR spectra can be summarized as follows: 1 H NMR (400 MHz, HFIP-d2): δ = 4.23 (m, n*4H, n ~ 14.3), 4.10 (m, 4H), 3.17 (m, 12H), 1.87-1.32 (multiple signals of aliphatic CH2 methylene) ppm. The average molecular weight of the repeating hard / soft block sections is about 2.5 kDa. The DSC results can be summarized as follows: DSC (10 °C / min, Figure 5A): Tm (top) = 20.9 °C (soft block melting), DSC (40 °C / min, Figure 5B): Tg = -38.0 °C. No second melting point of the hard block was observed up to 200 °C. However, in the final heating run to 250 °C at 10 °C / min (Figure 5C), a small and broad melting transition was observed at about 227 °C. In a DSC diagram, endothermic melting peaks plot downwards, whereas exothermic crystallization peaks plot upwards.

[0059] The non-porous aliphatic poly-urethane-urea-hexylene carbonate biomaterial had an elastic modulus of 3.6±0.03 MPa according to ASTM D638.

[0060] Preparation of biomaterial-capped PEKK bone anchors The implant 1 was manufactured by attaching the top and middle sections (4, 3) to a PEKK base section 2, which acts as a bone anchor. In a method according to an embodiment of the invention, the PEKK bone anchor was capped with a poly-urethane-urea-hexylene carbonate biomaterial by pressing small granules of an aliphatic polycarbonate polymer on top of and into the PEKK anchor. For this purpose, a custom-made press set-up was used. Different temperatures (100°C to about 150°C), compression forces (2 kN to about 4 kN) and methods were tested. The best results were obtained using a two-step procedure, using a temperature of 150°C and a compression force of 40 kN (4 tonnes, or 4000 kg, equivalent to a pressure of 1.4 GPa). Temperatures below 150° C. appeared to result in a non-uniformly pressed poly-urethane-urea-hexylene carbonate biomaterial layer (sections 3 and 4), whereas higher temperatures are less desirable since the urea groups of the poly-urethane-urea-hexylene carbonate biomaterial may subsequently degrade to some extent. In a first step, about 50 mg of polymer 12 was pressed onto the PEKK bone anchor for 15 minutes, and in a second step, about 2 mg of polymer 12 was added to the setup and the specimen was pressed under the same conditions (150° C. and 40 kN) for another 15 minutes. The specimen was then removed from the compression setup and then allowed to cool. After the second pressing step, the surface of the poly-urethane-urea-hexylene carbonate biomaterial layer (sections 3 and 4) on top of the base section 2 appeared to be substantially flat. The biomaterial was mostly transparent and colorless. Some flaking or fraying was observed at the edges of the biomaterial, which were removed using a scalpel.

[0061] The central hole (241, 242) in the base section 2 was approximately 4.5 mm deep and 2 mm in diameter. The hole was substantially filled with the poly-urethane-urea-hexylene carbonate biomaterial, and the attachment of the biomaterial to the PEKK base section 2 appeared to be very strong and robust. It proved virtually impossible to remove the biomaterial from the PEKK base section by force or to loosen the connection at the PEKK-biomaterial interface. All used instruments and accessories intended to come into contact with the PEKK base section 2 and / or the elastomeric biomaterial were rinsed with ethanol or isopropanol and then dried. After pressing and cutting any fraying, the PEKK-biomaterial plug implant was rinsed with isopropanol and dried. Plugs can also be manufactured in a sterile environment, if necessary.

[0062] As assessed by measurements, the PEKK base section was 6 mm in diameter and 6 mm in height (6 mm in height). The central cavity of the base section was approximately 2 mm in diameter and 4.5 mm in depth. The elastomeric biomaterial (aliphatic polycarbonate) placed on the PEKK base section was approximately 6 mm in diameter and 1 mm in height. Thus, the total height of the PEKK-biomaterial plug implant was approximately 7 mm.

[0063] The upper section 4 was pore-formed by drilling holes with an average diameter of 300 microns to give a final porosity of 50% by volume. The porous aliphatic poly-urethane-urea-hexylene carbonate biomaterial of the upper section 4 had an elastic modulus of 0.9±0.2 MPa according to ASTM D638.

[0064] The implant 1 may be implanted into an osteochondral defect 8, as shown in Figures 6A-6C. In a typical method, a hole is drilled into the cartilage defect (Figure 6A) extending into the subchondral bone, and a plug-shaped implant 1 is implanted into the drilled hole under certain pressure ("press-fit"), as shown in Figure 6B. Bone then grows onto, and in some embodiments into, the PEKK base section 2, fixing the implant 1. As shown in Figure 6C, the surrounding native cartilage 5 grows onto the top surface 41 of the top section 4, and new cartilage 5a is generated on the top of the implant 1. As also shown in Figure 6C, the height 20 of the base section 2, the height 30 of the non-porous middle section 3, and the height 40 of the porous top section 4 are selected such that the top surface 41 of the implant 1 is below the top surface 50 of the cartilage 5 present on the osteochondral structure (5, 6) when implanted, preferably over a distance 51 of 0.1-1 mm. In this case, this distance was about 0.5 mm. The osteochondral structure (5, 6) comprises a subchondral bone 6 and an overlying cartilage layer 5. A synovial cavity 7 is also typically present.

[0065] As also shown in Figures 6B and 6C, the height 20 of the base section 2, the height 30 of the non-porous middle section 3, and the height 40 of the porous top section 4 are selected such that the bottom surface 24 of the middle section 3 (or the top surface 24 of the base section 2) is approximately the same height as the bottom surface 51 of the cartilage layer 5 of the osteochondral structure (5, 6) when implanted.

[0066] Finally, an implant according to the embodiment shown in Figures 7A-7D may also be implanted in an osteochondral defect 8, as shown in Figures 8A-8C. Due to the spherical upper surface 41a of the top layer 4, this embodiment is able to regenerate a new cartilage layer 5a on the upper surface 41a of the upper section 4 of the implant 1, with a thickness that is approximately equal across the upper surface 41a. The result is that the radius of the upper surface 50 of the regenerated cartilage 5a may be approximately the same as the radius of the surrounding native cartilage layer 5 adjacent to the implant, thereby showing a continuity of radii.

[0067] Within the scope of the appended claims, many variations and applications of the invention will be apparent to those skilled in the art.

Claims

1. 1. An implant for replacement and regeneration of biological tissue in the form of a plug, comprising: a base section configured for fixation to bone tissue, a middle section configured for replacing cartilage tissue, and a top section configured for growing cartilage tissue on and into it, said middle and top sections comprising the same thermoplastic elastomeric material, which is porous in said top section and non-porous in said middle section, said base section comprising a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% relative to the total volume of the polyaryletherketone polymer.

2. 2. The implant of claim 1, wherein the base section comprises a core of a non-porous polyaryletherketone polymer and a circumferential shell of a porous polyaryletherketone polymer, the shell having a thickness less than 10% of a maximum diameter of the base section.

3. 3. The implant of claim 1 or 2, wherein the base section extends between a top surface and a bottom surface and comprises a layer of porous polyaryletherketone polymer, the layer adjacent the top surface and having a thickness that is less than 10% of a maximum height of the base section, and the pores of the polyaryletherketone polymer in the layer comprise a biocompatible elastomeric material.

4. The implant of any one of claims 1 to 3, wherein the top surface of the base section comprises irregularities or undulations.

5. The implant of any one of claims 1 to 4, wherein the base section includes a centrally located cavity containing a biocompatible elastomeric material.

6. The implant of any one of claims 1 to 5, wherein the base section comprises a non-porous polyaryletherketone polymer.

7. The implant of any one of claims 1 to 6, wherein the base section further comprises a phosphate mineral, including apatite.

8. The implant of any one of claims 1 to 7, wherein the base section includes an exterior surface having irregularities or contours.

9. An implant according to any one of claims 1 to 8, wherein the non-porous thermoplastic elastomeric material of the intermediate section has a modulus of elasticity at room temperature of less than 10 MPa.

10. 10. The implant of claim 1, wherein the porous thermoplastic elastomer material of the top section has a modulus of elasticity at room temperature that is less than 80% of the modulus of elasticity of the non-porous thermoplastic elastomer material of the middle section.

11. An implant described in any one of claims 1 to 10, wherein the height of the base section, the height of the intermediate section, and the height of the upper section are selected so that the upper surface of the implant, when implanted, is below the upper surface of the cartilage present on the osteochondral structure.

12. An implant as described in any one of claims 1 to 11, wherein the height of the base section, the height of the midsection, and the height of the upper section are selected so that the bottom surface of the midsection, when implanted, is approximately the same height as the bottom surface of the cartilage present on the osteochondral structure.

13. An implant according to any one of claims 1 to 12, comprising an upper section with a slightly curved upper surface, having a radius of curvature in the sagittal and / or medial-lateral plane in the range of 15mm to 150mm.

14. The implant of any one of claims 1 to 13, wherein the polyaryletherketone polymer of the base section comprises a reinforcing material selected from the group consisting of fibrous or particulate polymers and / or metals.

15. 15. The implant of any one of claims 1 to 14, wherein the thermoplastic elastomeric material comprises a linear block copolymer comprising urethane and urea groups and is substantially free of additional peptide compounds having cartilage regenerative properties.

16. The implant of claim 15 , wherein the thermoplastic elastomeric material further comprises a carbonate group.

17. 17. The implant of claim 16, wherein the thermoplastic elastomer material comprises a poly-urethane-bis-urea-alkylene carbonate.

18. The implant of any one of claims 1 to 17, wherein the thermoplastic elastomeric material is aliphatic.

19. 19. The implant of any one of claims 1-18, wherein the intermediate section comprises a core of non-porous elastomeric material and a circumferential shell of porous elastomeric material, the shell having a thickness less than 10% of a maximum diameter of the intermediate section.

20. A method for preparing an implant according to any one of claims 1 to 19, comprising the steps of: a) providing in a mold at room temperature an assembly of a base section comprising a substantially non-porous polyaryletherketone polymer having a porosity of less than 20% relative to the total volume of the polyaryletherketone polymer and granules of a thermoplastic elastomer material on top of said base section; b) closing the mold and heating the assembly to a temperature of 100° C. to 250° C. under a pressure of 1 to 2 GPa such that the thermoplastic elastomer material melts and fuses with the base section; c) cooling the assembly to room temperature to solidify the thermoplastic elastomer material and opening the mold; d) providing holes in a top section of the thermoplastic elastomeric material either before or after opening the mold; A method comprising:

21. 21. The method of claim 20, wherein after step b), the mold is opened, additional granules of the thermoplastic elastomeric material are added to the mold, and step b) is repeated.

22. An osteochondral structure comprising an implant as described in any one of claims 1 to 19, wherein an upper surface of the implant is below an upper surface of a cartilage layer on the osteochondral structure.

Citation Information

Patent Citations

  • Scaffold fixation device and method of making it

    JP2003024340A

  • Preparation, Characterization, Reinforcement of High Performance Reticulated Elastomeric Matrices and Use in Surgical Devices, Tissue Augmentation and / or Tissue Repair

    JP2009540923A

  • Cancellous Bone Implant for Cartilage Repair

    US20090149893A1

  • Biodegradable ostochondreal implant

    US20090164014A1

  • Hybrid polymer / metal plug for treating chondral defects

    US20110153028A1